Posts
March 30 2012
NeoStem, Inc. (NYSE Amex: NBS) sold 15,000,000 units at $0.40 per unit with $6 million in gross proceeds in an underwritten offering pursuant to the NeoStem's shelf registration statement . Each unit consists of one share of common stock and a warrant to purchase one share of common stock with a per share exercise price of $0.51. Maxim Group LLC acted as sole bookrunner. NeoStem has also granted Maxim a 45-day option to purchase up to an additional 2,250,000 units to cover over-allotments. EG&S acted as Maxim’s counsel.
March 30 2012
Epicept Corporation announced the closing of their Registered Direct offering in the amount of $1,065,000. EG&S acted as counsel to the placement agent.
March 28 2012
EDAP TMS S.A. announced the closing of their Registered Direct in the amount of $5,625,000. EG&S acted as counsel to the placement agent.
March 28 2012
Oncosec Medical Incorporated announced the closing of their Registered Direct offering in the amount of $7,750,000. EG&S acted as counsel to the placement agent.
March 26 2012
BGS Acquisition Corp. announced the closing of their initial public offering in the amount of $40,000,000. EG&S acted as counsel to BGS Acquisition Corp.
March 22 2012
Marina Biotech, Inc. announced the closing of their Registered Direct offering in the amount of $1,200,002. EG&S acted as counsel to the placement agent.
March 21 2012
GeoVax, Inc. announced the closing of their PIPE offering in the amount of $2,200,000. EG&S acted as counsel to the placement agent.
March 09 2012
Proteonomix, Inc. announced the closing of their PIPE offering in the amount of $3,804,991. EG&S acted as counsel to the placement agent.